Venous thromboembolism - Expanding therapeutic options

Abstract

Venous thromboembolism (VTE) is caused by the formation of blood clots within a vein resulting in vein occlusion and risk of blood clots travelling to the pulmonary arteries. VTE manifestations are deep vein thrombosis (DVT) and pulmonary embolism (PE). Until recently, standard therapy for VTE included daily injections of heparin with a subsequent transition to oral intake of vitamin K antagonist warfarin. Registration of the oral anticoagulant Xarelto in the RF as a treatment for deep vein thrombosis, pulmonary embolism and prevention of recurrent DVT and PE opens new opportunities for both professionals and patients.

Keywords

• венозная тромбоэмболия
• новые оральные антикоагулянты
• ривароксабан
• venous thromboembolism
• new oral anticoagulants
• rivaroxaban